Sarepta Therapeutics Inc
NASDAQ: SRPT
$119.02
+$4.94 (+4.3%)
Closing Price on February 5, 2025
SRPT Articles
24/7 Wall St. has collected three big FDA decisions coming up in February and added some color, along with the trading range and price target.
Published:
Last Updated:
Stocks tanked on Friday but were indicated sharply higher on Tuesday after the three-day weekend and after China’s gross domestic product met expectations. While investors may feel that every rally...
Published:
Last Updated:
While these were not the five biggest absolute losers of the week, of the active stocks, these all issued news or had news that took place and pushed the stocks down.
Published:
Last Updated:
Sarepta Therapeutics plunged early on Friday as the result of a failed clinical trial by BioMarin Pharmaceutical.
Published:
Last Updated:
A new Jefferies research report focuses on some biotech and specialty pharmaceutical stocks that have had some headline and clinical issues muddy the waters.
Published:
Last Updated:
24/7 Wall St. examines Valeant Pharmaceuticals and other biotech stocks with incredible gains or losses over the course of the past week.
Published:
Last Updated:
A new Jefferies research report highlights four top companies that could be looking at catalysts that in the very near term could have a huge impact on the stocks.
Published:
Last Updated:
We combed through the Merrill Lynch database and found three biotech companies that at one time or another, when they were much higher than they are now, had analysts going crazy.
Published:
Last Updated:
Sarepta announced a public offering of more than 3 million shares of its common stock at a price to the public of $39.00 per share, with a value of up to more than $145 million.
Published:
Sarepta Therapeutics announced additional clinical efficacy and safety data from its Phase 2b program of eteplirsen in patients with Duchenne muscular dystrophy.
Published:
Friday's top analyst upgrades, downgrades and initiations include BankUnited, Barrick Gold, ConocoPhillips, Michael Kors, Mylan, Viacom and Disney.
Published:
Tuesday's top analyst upgrades, downgrades and initiations include Apollo Education, Petrobras, Shopify, Fitbit, Sarepta Therapeutics and Lowe's.
Published:
Sarepta Therapeutics announces the completion of the rolling submission of a New Drug Application to the FDA for eteplirsen.
Published:
Last Updated:
Analysts are beginning to flock to Sarepta after the company made news surrounding a meeting with the FDA, not to mention the enormous boost that shares are getting from short covering.
Published:
Wednesday's top analyst upgrades, downgrades and initiations include Achillion Pharmaceuticals, Computer Sciences, Keurig Green Mountain, Sarepta Therapeutics and Splunk.
Published:
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.